Viewing nowExban Tablet 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

MFDS item code 201206965 · Approved 2012.09.27 · Insurance code 647803700
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used in patients with essential hypertension and heart failure. It is particularly effective in heart failure patients who are intolerant to ACE inhibitors. Additionally, it helps reduce the risk of mortality in clinically stable patients with left ventricular failure or dysfunction following myocardial infarction. Therefore, this medication is usefully applied in the treatment of conditions related to hypertension and decreased cardiac function.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take this medicine with water during a meal or between meals. It is recommended to take it at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect appears gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased up to a maximum of 320 mg daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily, and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine per dose twice daily; the dose may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine per dose twice daily. Over the following weeks, increase the dose, taking the patient’s tolerability into consideration, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, it is preferable not to exceed 80 mg daily. If doses of 80 mg or more daily are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1. Essential hypertension: The safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric use: The safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication may cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters. Therefore, it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, nursing mothers, patients with severe liver impairment, patients with severe kidney impairment, and patients with certain hereditary angioedema should not take this medication. Elderly patients, patients with hyperkalemia, patients with liver impairment, patients with heart valve diseases, and patients at risk of a sudden drop in blood pressure should use this medication cautiously. Side effects such as dizziness, hypotension, fatigue, headache, cough, etc., may occur during administration; in severe cases, kidney damage or hyperkalemia may occur, so symptoms should be closely monitored. A sudden drop in blood pressure may occur, so it is recommended to start with a low dose at the beginning and gradually increase while monitoring the patient's condition. This medication may interact with other blood pressure medications, diuretics, and potassium-sparing agents; therefore, it should be taken after consultation with a doctor or pharmacist, especially due to the risk of elevated potassium levels. It is advisable that pregnant or nursing mothers do not take this medication; if it must be taken, consulting a specialist and discontinuing nursing is recommended. The safety and efficacy of this medication have not been established in children and adolescents under 18 years of age, so usage should be avoided. In case of overdose, serious symptoms such as hypotension, altered consciousness, and shock may occur, so immediate medical attention is required.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture, ideally in a cool place at or below 30 degrees.
Oval film-coated tablets in orange with a grayish tint
100 tablets/bottle, 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.